15 Result(s)

Article

Discussion

M. Fukuoka in Bulletin of the International Association … (1978)

Article

Estimation of risks due to landslides

M. Fukuoka in Bulletin of the International Association … (1978)

Article

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer

A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan administered weekly with concurrent thoracic radiation therapy in patients with...

K Takeda, S Negoro, S Kudoh, K Okishio, N Masuda, M Takada… in British Journal of Cancer (1999)

Article

Association of essential hypertension in elderly Japanese with I/D polymorphism of the angiotensin-converting enzyme (ACE) gene

Recent evidence suggests that an insertion/deletion (I/D) polymorphism of the gene encoding angiotensin-converting enzyme (ACE) is associated with myocardial infarction and related cardiovascular diseases. We...

K. Yoshida, T. Ishigami, I. Nakazawa, A. Ohno, K. Tamura… in Journal of Human Genetics (2000)

Article

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

Dose-escalation study was performed to evaluate the maximum tolerated dose, recommended dose and toxicity profile of weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in patients wi...

M Yamada, S Kudoh, H Fukuda, K Nakagawa, N Yamamoto… in British Journal of Cancer (2002)

Article

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplati...

S Negoro, N Masuda, Y Takada, T Sugiura, S Kudoh, N Katakami… in British Journal of Cancer (2003)

Article

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-cell lung cancer (NSCLC). A randomised phase II study compared their efficacy a...

N Yamamoto, M Fukuoka, S-I Negoro, K Nakagawa, H Saito… in British Journal of Cancer (2004)

Article

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour activity, we conducted a combination phase I study in advanced non-small-cell lung c...

T Kurata, K Tamura, N Yamamoto, T Nogami, T Satoh, H Kaneda… in British Journal of Cancer (2004)

Article

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B₁₂ in Japanese patients with solid tumours

The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with folate and vitamin B12 supplementation (FA/VB₁₂) in Japanese patients with solid tumours an...

K Nakagawa, S Kudoh, K Matsui, S Negoro, N Yamamoto, J E Latz… in British Journal of Cancer (2006)

Article

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo

TZT-1027 is a novel anticancer agent that inhibits microtubule polymerisation and manifests potent antitumour activity in preclinical models. We have examined the effect of TZT-1027 on cell cycle progression a...

Y Akashi, I Okamoto, M Suzuki, K Tamura, T Iwasa, S Hisada… in British Journal of Cancer (2007)

Article

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

The expression and activity of the epidermal growth factor receptor (EGFR) are determinants of radiosensitivity in several tumour types, including non-small cell lung cancer (NSCLC). However, little is known o...

Y Akashi, I Okamoto, T Iwasa, T Yoshida, M Suzuki, E Hatashita… in British Journal of Cancer (2008)

Article

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung c...

K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh… in British Journal of Cancer (2008)

Article

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor o...

T Iwasa, I Okamoto, K Takezawa, K Yamanaka, T Nakahara, A Kita… in British Journal of Cancer (2010)

Article

Identification of thymidylate synthase as a potential therapeutic target for lung cancer

Thymidylate synthase (TS), a key enzyme in the de novo synthesis of thymidine, is an important chemotherapeutic target for malignant tumours including lung cancer. Although inhibition of TS has an antiproliferati...

K Takezawa, I Okamoto, S Tsukioka, J Uchida, M Kiniwa… in British Journal of Cancer (2010)

Article

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival i...

K Eto, H Kawakami, M Kuwatani, T Kudo, Y Abe, S Kawahata… in British Journal of Cancer (2013)